

**Recombinant Zoster Vaccine (RZV)
SHINGRIX®**

Pathophysiology	<ul style="list-style-type: none"> • A manifestation of the reactivation of varicella zoster virus which, as a primary infection, produces chickenpox (varicella). Following initial infection, the virus remains latent in the dorsal root or cranial sensory ganglia until it reactivates, producing zoster. • Zoster is characterized by a unilateral, painful, vesicular cutaneous eruption with a dermatomal distribution.
Vaccine Description	Recombinant zoster vaccine, adjuvanted
Dose & Route	<ul style="list-style-type: none"> • 0.5 mL single dose unit given IM • Reconstituted with the accompanying vial of ASO1_B adjuvanted suspension component
Administration Schedule & Minimum Intervals	<p>Dose Minimum Age 1...50 years and older 2...2 to 6 months after dose 1; minimum interval 4 weeks; repeat dose if administered too soon regardless of previous herpes zoster or history of zoster vaccine live (ZVL, Zostavax) vaccination</p> <ul style="list-style-type: none"> • RZV is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥ 50 years. • RZV is recommended for prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL). • RZV may be used in adults aged ≥ is preferred over ZVL for the prevention of herpes zoster and related complications. • RZV may be used in adults aged ≥ 50 years irrespective of prior receipt of varicella vaccine or ZVL and does not require screening for a history of chickenpox (varicella).

Contraindications	<ul style="list-style-type: none"> • History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
Precautions	<ul style="list-style-type: none"> • Moderate or severe acute illness
Special Considerations	<ul style="list-style-type: none"> • Consider delaying RZV until after pregnancy if RZV is otherwise indicated • Sever immunocompromising conditions (including HIV infection regardless of CD4 count**): 2-dose series recombinant zoster vaccine (RZV, Shingrix) 2-6 months apart; minimum interval 4 weeks; repeat dose if administered too soon. • If there is no documented history of varicella, varicella vaccination, or herpes zoster providers should refer to the clinical considerations for use of RZV in immunocompromised adults aged ≥ 19 years and the ACIP varicella vaccine recommendations for further guidance; www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm • This vaccine is not a substitute for varicella vaccine and should never be administered to children. • Not indicated for treatment of herpes zoster (shingles) or postherpetic neuralgia • The duration of protection after vaccination is unknown. • RZV is stored in the refrigerator at 36°F to 46°F (2°C to 8°C) • After reconstitution, administer immediately or store refrigerated and use within 6 hours. Discard reconstituted vaccine if not used within 6 hours.